Selumetinib ( AZD@ , ARRY-@ ) + docetaxel increases median overall survival ( OS ) and significantly improves progression-free survival ( PFS ) and objective response rate ( ORR ) compared with docetaxel alone in patients with KRAS mutant , stage IIIB/IV non-small-cell lung cancer ( NSCLC ; NCT@ ) .